PROJECT TEAM
Juan Luis Vásquez, MD, PhD, , Associate Professor, Urologist and head of Urothelial Cancer Team at the Department of Urology, Zealand University Hospital
Julie Gehl, MD, PhD, Clinical Professor, Department of Oncology, Zealand University Hospital.
Rose Laursen, MD, PhD student. Department of Urology, Zealand University Hospital.
THE NEED
Bladder cancer treatments are costly, involve multiple surgeries and instillations, and significantly impact patients' quality of life. Current therapies often cause severe side effects, require prolonged follow-up, and are not suitable for all patients, especially those unfit for invasive surgeries like cystectomy.
THE SOLUTION
The novel electrode enables calcium electroporation (CaEP), a technique that uses electric pulses to permeabilize cancer cells, causing selective necrosis and activating an anti-tumor immune response. CaEP is less invasive, avoids lengthy treatment regimens, and has demonstrated promising safety and efficacy in clinical studies and case reports.
Bladder Cancer Electroporation - Sjællands Universitetshospital
Call 7 - 2025
500.000 DKK
Clinical Area
Urology
Technology
MedTech
PROJECT SUMMARY
Bladder Cancer Electroporation is a minimally invasive, cost-effective treatment using calcium electroporation (CaEP) to selectively destroy cancer cells while preserving healthy tissue. This innovative approach aims to reduce side effects, hospital visits, and overall treatment costs for bladder cancer patients.
CLINICAL IMPACT
CaEP can replace or reduce the need for invasive procedures such as cystectomy, lowering the risk of complications and 90-day mortality rates (up to 8% for cystectomy). It reduces the burden of repeated intravesical treatments like BCG, which cause side effects in up to 70% of patients. The therapy offers same-day discharge, fewer hospital visits, better patient outcomes, and significant cost savings for healthcare systems.